Novartis Pelacarsen Lowers Lp(a) Levels but Shows No Reduction in Major Cardiovascular Events in Phase 3 HORIZON Trial

The HORIZON trial randomized 8,323 patients with established cardiovascular disease and elevated Lp(a) to monthly pelacarsen or placebo. Primary endpoint events occurred at identical rates in both arms, confirming that Lp(a) reduction alone did not translate into fewer clinical events. The result challenges the assumption that Lp(a) is a modifiable causal driver amenable to isolated pharmacologic attack.

Novartis’s strategy mirrors prior industry bets on surrogate lipid markers that later failed to deliver hard outcomes. Observational data link high Lp(a) to excess risk, yet genetic and epidemiologic studies show the particle often coexists with other atherogenic traits. Health-equity concerns arise because Lp(a) testing and advanced therapies remain concentrated in high-resource systems, leaving genetically at-risk populations in lower-income regions without access even if future agents succeed.

The negative outcome will likely shift pipelines toward combination regimens or earlier intervention. Regulators may now demand larger, longer trials with composite mortality endpoints before approving any Lp(a)-specific drug.